Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: A single-center experience

Modern Rheumatology

Volumn 19, Issue 4, 2009, Pages 420-426

  Nakabayashi, Kimimasa ^a   Arimura, Yoshihiro ^a   Yoshihara, Ken ^a   Fukuoka, Toshihiro ^a   Karube, Miho ^a   Yamato, Tunee ^a   Koji, Hitoshi ^a   Ikegaya, Noriko ^a   Ohtuka, Takako ^a   Kawashima, Sohko ^a   Sudo, Miyako ^a   Yamada, Akira ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical subtype; MPO ANCA; Prognosis; Relapse; Vasculitis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; MIZORIBINE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; STEROID;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; CANCER MORTALITY; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG PULSE THERAPY; EAR NOSE THROAT DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; JAPANESE; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; LUNG FIBROSIS; LUNG HEMORRHAGE; MALE; MENINGITIS; MUSCULOSKELETAL DISEASE; MYELOPEROXIDASE TYPE ANCA ASSOCIATED VASCULITIS; NEURITIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RECURRENT DISEASE; SURVIVAL RATE; SYSTEMIC DISEASE;

AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEROXIDASE; PREDNISOLONE; PROGNOSIS; SURVIVAL RATE; VASCULITIS;

EID: 68549088732     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0182-0     Document Type: Article

References (15)

1. Jennette JC, Falk RJ, Andrassy K, Bacon P, Churg J, Gross WL, et al. Nomenclature of systemic vasculitis. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-92.
2. Falk RJ, Hogan S, Carey TS, Jennette JC, the Glomerular Disease Collaborative Network. Clinical course of antineutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med. 1990;113:656-63.
3. Geffriand-Ricouard C, Noel LH, Chauveau D, Houhou S, Grundfeld JP, Lesavre P. Clinical spectrum associated with ANCA defined antigen specificities in 98 selected patients. Clin Nephrol. 1993;39:125-36.
4. Hogan S, Nachman PH, Wilkman AS, Jennette JC, Falk RJ, the Glomerular Disease Collaborative Network. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23-32.
5. Westman KWA, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9:842-52.
6. Bajema IM, Hogan EC, Hermans J, Noël LH, Waldherr R, Ferrario F, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751-8.
7. Kawamoto S, Kawamura T, Utsunomiya Y, Kawaguchi Y, Hosoya T. Analysis of risk factor for patients and renal survival in anti-myeloperoxidase antibody (MPO-ANCA) associated glomerulonephritis (in Japanese, abstract in English). Jpn J Nephrol. 1999;41:719-25.
8. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732-42.
9. Japanese Study Group for MPO-ANCA-Associated Vasculitis (JMAAV). The prospective cohort study for MPO-ANCA associated vasculitis treated according to the standard protocol regimen (directed by Prof S.Ozaki, in Japanese). 2006 Annual Report on Intractable Vasculitis Syndrome supported by the Ministry of Health, Welfare, and Labour of Japan; 2006. pp. 199-273.
10. Nagakawa T, Arimura Y, Yoshida M, Hiromura N, Naruse T, Nishiki N, et al. Fundamental and clinical evaluation of MPO ELISA kit (NISSHO) (in Japanese). Lab Mach Reag. 1995;18:127-35.
11. Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with a systemic vasculitis. Q J Med. 1993;86:779-89.
12. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic auto-antibody associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:33-4.
13. Nakabayashi K, Kobayashi S, Matsuoka Y, Yoshida T, Yoshida M, Ozaki S, et al. Statistical analysis of infectious death in patients receiving immunosuppressive drugs with medium-and small-vessel vasculitides (in Japanese, abstract in English). 2000 Annual Report for the Refractory Vasculitis Syndrome (Chief: Prof H. Hashimoto) supported by Ministry of Health, Welfare, and Labour of Japan; 2001. pp. 58-68.
14. Sakai H, Kurokawa K, Koyama T, Arimura Y, Kida H, Shigematsu S, et al. The treatment guideline for rapidly progressive glomerulonephritis (in Japanese). Jpn J Nephrol. 2002;44:55-82.
15. Fujii A, Tomizawa K, Arimura Y, Nagasawa T, Uhashi YY, Hiyama S, et al. Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. Clin Nephrol. 2000;53:242-52.